Delivery Order SPE2DB25D3404-SPE2DB25FUPKM
- Not listed
- The Defense Logistics Agency awarded a $3,465.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of August 15, 2025. This non-set-aside competitive award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery order is to be fulfilled at AmerisourceBergen's corporate office location in...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside competitive award is scheduled for completion by October 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $17,908.00 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vial 5ML, a rabies immunoglobulin product used in post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 19, 2025, and represents a continuation of the company's ongoing pharmaceutical supply relationship with federal healthcare systems. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 15, 2025, and represents a non-set-aside procurement. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as the place of performance for this medical supply delivery. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,372.40 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a $16,632.48 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency awarded a $1,732.55 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with an ultimate completion date of August 11, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,465.10 on August 19, 2025, for HYPERRAB 300 Unit/mL vials. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania, and an ultimate completion date of September 10, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUPKMDelivery Order
The Defense Logistics Agency issued a delivery order valued at $3,465.10 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This non-set-aside, firm fixed-price delivery order was awarded on July 23, 2025, with an ultimate completion date of August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. HYPERRAB is a rabies immunoglobulin (human) product used for post-exposure prophylaxis and represents part of the company's extensive portfolio of specialized pharmaceutical supplies provided to federal military and healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen Drug Corp's continued awards under this DLA framework reflect its capability to meet competitive federal procurement standards for critical medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 7/23/25 |